Treatment availability depends on eligibility, clinician review, and applicable requirements
Tirzepatide produces about 20-22% weight loss
At 53, she exercised five days a week and tracked every calorie
If retatrutide's greater efficacy in weight and metabolic parameters translates to cardiovascular outcome data of comparable or superior magnitude, the case for its use as a longevity intervention, not merely an obesity treatment, will be scientifically compelling
Eli Lilly and Company reported positive topline results from the Triumph-2 and Triumph-3 pivotal Phase III trials evaluating Retatrutide
One strategy some research users report is maintaining a lower maintenance dose rather than stopping entirely, similar to how the clinical trial community is now discussing long-term low-dose maintenance for GLP-1 class medications broadly